526 related articles for article (PubMed ID: 22726074)
1. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
Vicente-Valor MI; Garcia-Llopis P; Mejia Andujar L; Antonino de la Camara G; García del Busto N; Lopez Tinoco MJ; Quintana Vergara B; Peiro Vilaplana C; Dominguez Moran JA; Sánchez Alcaraz A
J Clin Pharm Ther; 2013 Feb; 38(1):71-3. PubMed ID: 22726074
[TBL] [Abstract][Full Text] [Related]
2. Successful intrathecal baclofen therapy for seronegative stiff-person syndrome: a case report.
Ho BL; Shih PY
Acta Neurol Taiwan; 2008 Sep; 17(3):172-6. PubMed ID: 18975523
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O
Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
[TBL] [Abstract][Full Text] [Related]
4. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
5. Focal stiff-person syndrome.
Fiol M; Cammarota A; Rivero A; Pardal A; Nogués M; Correale J
Neurologia; 2001 Feb; 16(2):89-91. PubMed ID: 11257937
[TBL] [Abstract][Full Text] [Related]
6. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
8. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
9. THC:CBD spray and MS spasticity symptoms: data from latest studies.
Rekand T
Eur Neurol; 2014; 71 Suppl 1():4-9. PubMed ID: 24457846
[TBL] [Abstract][Full Text] [Related]
10. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
Keating GM
Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
12. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
[TBL] [Abstract][Full Text] [Related]
13. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
14. The stiff-person syndrome. Case report.
Piovano C; Piattelli M; Spina T; Iervese G; Bosco G
Minerva Anestesiol; 2002 Nov; 68(11):861-5. PubMed ID: 12538969
[TBL] [Abstract][Full Text] [Related]
15. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
16. Cannabis; adverse effects from an oromucosal spray.
Scully C
Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal baclofen pump implantation in a case of stiff person syndrome.
Maramattom BV
Neurol India; 2010; 58(1):115-7. PubMed ID: 20228478
[TBL] [Abstract][Full Text] [Related]
18. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
[TBL] [Abstract][Full Text] [Related]
20. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Celius EG; Vila C
Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
